Abstract
Rationale
Psychological processes such as expectancy, attention, and affect directly influence clinical outcomes. These factors are grouped together as “nonspecific” factors, or placebo effects, in the medical literature, and their individual contributions are rarely considered. The pain-reducing effects of analgesic treatments may reflect changes in these psychological factors, rather than pure drug effects on pain. Furthermore, drug effects may not be isolated by drug vs. placebo comparisons if drugs interact with relevant psychological processes.
Objectives
We sought to determine whether the analgesic effects of opioid and placebo treatment are mediated by changes in attention, expectancy, or affect.
Methods
We crossed intravenous administration of a potent opioid analgesic, remifentanil, with information about drug delivery (treatment expectancy or placebo) using a balanced placebo design. We measured drug and treatment expectancy effects on pain, attention, and responses to emotional images. We also examined interactions with cue-based expectations about noxious stimulation or stimulus expectancy.
Results
Pain was additively influenced by treatment expectancy, stimulus expectancy, and drug concentration. Attention performance showed a small but significant interaction between drug and treatment expectancy. Finally, remifentanil enhanced responses to both positive and negative emotional images.
Conclusions
The pain-relieving effects of opioid drugs are unlikely to be mediated by changes in threat or affective processing. Standard open-label opioid administration influences multiple clinically relevant cognitive and emotional processes. Psychological factors can combine with drug effects to influence multiple outcomes in distinct ways. The influence of specific psychological factors should be considered when developing and testing pharmacological treatments.
Similar content being viewed by others
References
Arvidsson U, Riedl M, Chakrabarti S, Lee JH, Nakano AH, Dado RJ et al (1995) Distribution and targeting of a mu-opioid receptor (MOR1) in brain and spinal cord. J Neurosci 15(5 Pt 1):3328–3341
Atlas LY, Wager TD (2012) How expectations shape pain. Neurosci Lett 520(2):140–148
Atlas LY, Bolger N, Lindquist MA, Wager TD (2010) Brain mediators of predictive cue effects on perceived pain. J Neurosci 30(39):12964–12977
Atlas LY, Whittington RA, Lindquist MA, Wielgosz J, Sonty N, Wager TD (2012) Dissociable influences of opiates and expectations on pain. J Neurosci 32(23):8053–8064
Bates D, Maechler M, Bolker B (2011) Lme4: Linear mixed-effects models using S4 classes. R package version 0.999375-40. http://CRAN.R-project.org/package=lme4.
Benedetti F, Carlino E, Pollo A (2011) How placebos change the patient’s brain. Neuropsychopharmacology 36(1):339–354
Bijur PE, Silver W, Gallagher EJ (2001) Reliability of the visual analog scale for measurement of acute pain. Acad Emerg Med 8(12):1153–1157
Bingel U, Wanigasekera V, Wiech K, Mhuircheartaigh RN, Lee MC, Ploner M et al (2011) The effect of treatment expectation on drug efficacy: imaging the analgesic benefit of the opioid remifentanil. Sci Transl Med 3(70):1–10
Buhle JT, Stevens BL, Friedman JJ, Wager TD (2012) Distraction and placebo: two separate routes to pain control. Psychol Sci 23(3):246–253
Chapman CR, Casey KL, Dubner R, Foley KM, Gracely RH, Reading AE (1985) Pain measurement: an overview. Pain 22(1):1–31
Cohen SP, Christo PJ, Wang S, Chen L, Stojanovic MP, Shields CH et al (2008) The effect of opioid dose and treatment duration on the perception of a painful standardized clinical stimulus. Reg Anesth Pain Med 33(3):199–206
Colloca L, Benedetti F (2005) Placebos and painkillers: is mind as real as matter? Nat Rev Neurosci 6(7):545–552
Colloca L, Miller FG (2011) How placebo responses are formed: a learning perspective. Phil Trans R Soc B 366:1859–1869
Eccleston C, Crombez G (1999) Pain demands attention: a cognitive-affective model of the interruptive function of pain. Psychol Bull 125(3):356–366
Efron B, Tibshirani RJ (1993) An Introduction to the Bootstrap. Chapman and Hall, New York
Finniss DG, Kaptchuk TJ, Miller F, Benedetti F (2010) Biological, clinical, and ethical advances of placebo effects. Lancet 375(9715):686–695
Flaten MA, Aslaksen PM, Finset A, Simonsen T, Johansen O (2006) Cognitive and emotional factors in placebo analgesia. J Psychosom Res 61(1):81–89
Frost JJW, Henry N Jr, Dannals RF, Ravert HT, Links JM, Wilson AA, Burns HD, Wong DF, McPherson RW, Rosenbaum AE, Kuhar MJ, Snyder SH (1985) Imaging opiate receptors in the human brain by positron tomography. J Comput Assist Tomogr 9(2):231–236
Gospic K, Gunnarsson T, Fransson P, Ingvar M, Lindefors N, Petrovic P (2008) Emotional perception modulated by an opioid and a cholecystokinin agonist. Psychopharmacology 197(2):295–307
Gracely RH, Dubner R, McGrath PA (1979) Narcotic analgesia: fentanyl reduces the intensity but not the unpleasantness of painful tooth pulp sensations. Science 203(4386):1261–1263
Gracely RH, Dubner R, Wolskee PJ, Deeter WR (1983) Placebo and naloxone can alter post-surgical pain by separate mechanisms. Nature 306(5940):264–265
Gracely RH, Dubner R, Deeter WR, Wolskee PJ (1985) Clinicians’ expectations influence placebo analgesia. Lancet 1(8419):43
Johnston NE, Atlas LY, Wager TD (2012) Opposing effects of expectancy and somatic focus on pain. PLoS ONE 7(6):e38854
Jones AK, Friston KJ, Qi LY, Harris M, Cunningham VJ, Jones T et al (1991) Sites of action of morphine in the brain. Lancet 338(8770):825
Kaptchuk TJ (2002) The placebo effect in alternative medicine: can the performance of a healing ritual have clinical significance? Ann Intern Med 136(11):817–825
Kirsch I (1985) Response expectancy as a determinant of experience and behavior. Am Psychol 40(11):1189–1202
Kirsch I (1997) Response expectancy theory and application: a decennial review. Appl Prev Psychol 6:69–79
Kupers RC, Konings H, Adriaensen H, Gybels JM (1991) Morphine differentially affects the sensory and affective pain ratings in neurogenic and idiopathic forms of pain. Pain 47(1):5–12
Lang PJ, Bradley MM, Cuthbert BN (1998) Emotion, motivation, and anxiety: brain mechanisms and psychophysiology. Biol Psychiatry 44(12):1248–1263
Legrain V, Damme SV, Eccleston C, Davis KD, Seminowicz DA, Crombez G (2009) A neurocognitive model of attention to pain: behavioral and neuroimaging evidence. Pain 144(3):230–232
Liberzon I, Zubieta JK, Fig LM, Phan KL, Koeppe RA, Taylor SF (2002) μ-Opioid receptors and limbic responses to aversive emotional stimuli. Proc Natl Acad Sci 99(10):7084–7089
Minto CF, Schnider TW, Egan TD, Youngs E, Lemmens HJ, Gambus PL et al (1997a) Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. Anesthesiology 86(1):10–23
Minto CF, Schnider TW, Shafer S (1997b) Pharmacokinetics and pharmacodynamics of remifentanil. II. Model application. Anesthesiology 86(1):24–33
Mueller M, Bjorkedal E, Kamping S (2012) Manipulation of expectancy and anxiety in placebo research and their effects on opioid-induced analgesia. J Neurosci 32(41):14051–14052
Petrovic P, Dietrich T, Fransson P, Andersson J, Carlsson K, Ingvar M (2005) Placebo in emotional processing–induced expectations of anxiety relief activate a generalized modulatory network. Neuron 46(6):957–969
Price DD, Von der Gruen A, Miller J, Rafii A, Price C (1985) A psychophysical analysis of morphine analgesia. Pain 22(3):261–269
Price DD, Milling LS, Kirsch I, Duff A, Montgomery GH, Nicholls SS (1999) An analysis of factors that contribute to the magnitude of analgesia in an experimental paradigm. Pain 83:147–156
Rohsenow DJ, Marlatt GA (1981) The balanced placebo design: methodological considerations. Addict Behav 6(2):107–122
Ross S, Krugman A, Lyerly S, Clyde D (1962) Drugs and placebos: a model design. Psychol Rep 10:383–392
Shih S-I, Sperling G (2002) Measuring and modeling the trajectory of visual spatial attention. Psychol Rev 109(2):260–305
Sprenger C, Eippert F, Finsterbusch J, Bingel U, Rose M, Buchel C (2012) Attention modulates spinal cord responses to pain. Curr Biol 22(11):1019–1022
Vase L, Riley JL, Price DD (2002) A comparison of placebo effects in clinical analgesic trials versus studies of placebo analgesia. Pain 99:443–452
Wager TD, Atlas LY, Lindquist MA, Roy M, Woo C, Kross E (2013) An fMRI-based neurologic signature of physical pain. N Engl J Med 368(15):1388–1397
Zacny JP (1995) A review of the effects of opioids on psychomotor and cognitive functioning in humans. Exp Clin Psychopharmacol 3(4):432–466
Zhang W, Luo J (2009) The transferable placebo effect from pain to emotion: changes in behavior and EEG activity. Psychophysiology 46(3):626–634
Zubieta JK, Ketter TA, Bueller JA, Xu Y, Kilbourn MR, Young EA et al (2003) Regulation of human affective responses by anterior cingulate and limbic mu-opioid neurotransmission. Arch Gen Psychiatry 60(11):1145–1153
Acknowledgments
The authors would like to thank Namema Amendi and Steven Dashnaw for helpful assistance in data collection, and Stephen Shafer for assistance with the pharmacokinetic model of remifentanil. This work was funded by the NIH (NIMH RO1MH076136 and NIDA RO1DA027794, awarded to T.D.W.). The authors declare no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Atlas, L.Y., Wielgosz, J., Whittington, R.A. et al. Specifying the non-specific factors underlying opioid analgesia: expectancy, attention, and affect. Psychopharmacology 231, 813–823 (2014). https://doi.org/10.1007/s00213-013-3296-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-013-3296-1